



# HHS Public Access

Author manuscript

*Nat Rev Mol Cell Biol.* Author manuscript; available in PMC 2016 January 22.

Published in final edited form as:

*Nat Rev Mol Cell Biol.* 2015 April ; 16(4): 232–244. doi:10.1038/nrm3966.

## Signalling scaffolds and local organization of cellular behaviour

Lorene K. Langeberg and John D. Scott

Howard Hughes Medical Institute and Department of Pharmacology, University of Washington, 1959 NE Pacific Street, Seattle, Washington 98195, USA

### Abstract

Cellular responses to environmental cues involve the mobilization of GTPases, protein kinases and phosphoprotein phosphatases. The spatial organization of these signalling enzymes by scaffold proteins helps to guide the flow of molecular information. Allosteric modulation of scaffolded enzymes can alter their catalytic activity or sensitivity to second messengers in a manner that augments, insulates or terminates local cellular events. This Review examines the features of scaffold proteins and highlights examples of locally organized groups of signalling enzymes that drive essential physiological processes, including hormone action, heart rate, cell division, organelle movement and synaptic transmission.

---

A well-worn adage, rediscovered by successive generations of researchers, is that ‘the longer a topic is investigated, the more complex the questions become’. This is certainly true for biomedical scientists, who grapple with the ever-accumulating molecular details of cell regulation. Within the perceived chaos of the cell, local organization of signalling enzymes guarantees the fidelity of information processing. Breakdown of this molecular order can result in disease. The concept of protein scaffolds as control centres for the integration and dissemination of subcellular information has evolved considerably during the past 25 years.

The protein scaffold model originates from three conceptual and technical breakthroughs in the late 1980s and early 1990s. These were: the realization that protein-interaction modules are the building blocks of macromolecular assemblies<sup>1–6</sup>; the use of yeast two-hybrid and proteomic analyses as a universal means to systematically identify protein–protein interactions<sup>7,8</sup>; and innovative genetic screens in lower organisms that uncovered functional relationships between signalling elements<sup>9–11</sup>. As investigators from different disciplines exploited these advances, it was soon recognized that a substantial proportion of human genes encode enzyme-binding proteins<sup>12,13</sup>. We now know that these ancillary signalling elements participate in the organization of MAPK cascades; the subcellular targeting of

---

*Correspondence to J.D.S.*, [scottjdw@uw.edu](mailto:scottjdw@uw.edu).

This Review is dedicated to the memory of Tony Pawson, our friend, our colleague and a pioneer in this field.

#### DATABASES

**RCSB Protein Data Bank:**

<http://www.rcsb.org/pdb/home/home.do>

3C9W | 3N5U | 3J4Q

**ALL LINKS ARE ACTIVE IN THE ONLINE PDF**

#### Competing interests statement

The authors declare no competing interests.

second-messenger-regulated protein kinases and phosphoprotein phosphatases; and the temporal control of rapid signalling events, such as muscle contraction, synaptic transmission and retrograde transport of organelles along microtubules.

At the dawn of the twenty-first century, many of these enzyme-binding proteins had been classified as adaptor, docking, anchoring or scaffold proteins<sup>14</sup>. Although it is cumbersome and confusing, this arbitrary terminology is now firmly entrenched in the signalling community. However, despite its utility, it is often difficult to assign an individual protein to a single class. Therefore, for the purposes of this Review, we propose that adaptor proteins are soluble proteins that contain several modular protein-interaction domains within their structure (FIG. 1a). Prototypical examples include growth factor receptor-bound protein 2 (GRB2) and SHC1, both of which are composed of SRC homology 2 (SH2) and SH3 domains and enable selective and simultaneous recruitment of several signalling elements<sup>15,16</sup> (FIG. 1a). Similarly, docking proteins are composed of modular protein-interaction domains, with a distinguishing feature being that they sequester signalling components at the cell membrane next to an activating receptor (FIG. 1b). Proteins emblematic of this class include insulin receptor substrate 1 (IRS1), IRS2, IRS3 and IRS4 (FIG. 1b), which help to transmit signals from insulin to various intracellular PI3K–AKT and MAPK cascades; and fibroblast growth factor receptor substrate 2 $\alpha$  (FRS2 $\alpha$ ), which links its receptor to several downstream signalling pathways<sup>17–19</sup>.

In contrast to the aforementioned examples of adaptor proteins and docking proteins, the delineation between anchoring and scaffold proteins is much less clear<sup>12,20,21</sup>. In fact, these terms have been used interchangeably to describe the same molecule; in this Review, we use the term scaffold protein. Here, we identify three features that are often attributable to this burgeoning class of signal-organizing proteins (FIG. 1c – e). First, they can be multivalent binding proteins that hold members of a transduction cascade in place to optimize signal relay (FIG. 1c). Second, they can be non-catalytic organizational elements that focus enzyme activity at a particular site of action (FIG. 1d). Third, they can be structural components that provide a molecular platform for the recruitment of signal transduction and signal termination enzymes to enhance the bidirectional control of cellular processes (FIG. 1e).

As these three features are generic characteristics of this expanding protein class, it is important to note that individual scaffold proteins may only fulfil one or two of these functional roles (FIG. 1c – e). Recent technical advances are leading to a rapid expansion of our understanding of the composition and structure of these signalling scaffolds. Data regarding the nature of macromolecular complexes are accumulating, and it is becoming clear that protein–protein interactions that induce conformational changes, confer catalytic activity or create an entirely new structural surface are as important for cell signalling as protein post-translational modifications. Specific examples of how scaffold proteins exhibit all of these characteristics are discussed in the following sections.

## Pseudokinases and pseudophosphatases

Of the 544 protein kinases (G. Manning, personal communication) that constitute the human kinome, 55 are currently known to be pseudokinases — kinase-like proteins that lack the key residues essential for catalytic activity<sup>22–24</sup> (BOX 1). Rather than functioning enzymatically, pseudokinases and their counterparts, pseudophosphatases, regulate phosphorylation events by functioning as allosteric modulators of other signalling enzymes<sup>25,26</sup>. Another important function of pseudokinases and pseudophosphatases is in kinase scaffolding, either directly by acting as kinase scaffolds or indirectly by functioning together with other scaffold proteins. As a result, these seemingly inert signalling elements are increasingly viewed as integral components of signalling pathways. Although there is considerable interest in the propagation of oncogenic signals by receptor tyrosine kinase-like pseudokinases — such as the epidermal growth factor (EGF) receptor family member HER3 (also known as ERBB3)<sup>27,28</sup> — we limit our discussion here to serine/threonine kinase-like pseudokinases.

### Pseudokinases as scaffold proteins

One exciting new concept is that the activation of certain serine/threonine kinases requires the formation of a larger complex in which a pseudokinase functions cooperatively as a scaffold protein (FIG. 2a,b). Liver kinase B1 (LKB1; also known as STK11) is a tumour suppressor protein kinase that regulates cellular energy status, cell proliferation and cell polarity<sup>29–31</sup>. A defining feature of LKB1 is that it is not activated by the phosphorylation of its A loop, but instead it is induced into the active state through interaction with the pseudokinase STRAD<sup>32</sup>(FIG. 2a). Structural studies have shown that STRAD adopts an active kinase-like conformation through its interactions with nucleotides and with the horseshoe-shaped calcium-binding protein MO25 (also known as CAB39)<sup>33,34</sup>. The closed conformation of the ATP-bound STRAD engages LKB1, and the concomitant binding of MO25 to LKB1 stabilizes its active conformation<sup>35</sup>(FIG. 2a). These studies have elucidated distinct regulatory roles for each component of the STRAD-LKB1-MO25 ternary complex.

### Pseudokinases with multiple functions

Although many pseudokinases have been identified as allosteric modulators or scaffold proteins, both properties often reside within the same protein. For example, kinase suppressor of RAS (KSR) is a multifunctional binding protein that brings together and modulates members of the conventional ERK cascade: rapidly accelerated fibrosarcoma (RAF) kinases, MEK and ERK<sup>36,37</sup>. This RAF–MEK–ERK triad relays signals that emanate from cell surface receptors and that are transmitted through the small guanosine triphosphatase RAS to the nucleus (FIG. 2b). Phosphorylation-dependent activation of ERK stimulates the expression of genes that drive proliferation, differentiation and other cellular processes.

Although early biochemical studies suggested that the pseudokinase scaffold protein KSR lacks the ability to catalyse phosphorylation<sup>36</sup>, recent *in vitro* work indicates that, in certain contexts, KSR can phosphorylate MEK<sup>38</sup>. This provides an interesting new twist to the function of KSR, which was previously considered simply as an inert signalling component.

Although this classic pseudokinase is now thought by some to have intrinsic phosphotransferase activity, it should be noted that the function of these KSR-mediated phosphorylation sites on MEK is unclear<sup>38</sup>. A combination of X-ray crystallography and chemical genetic approaches has determined that formation of a KSR–RAF–MEK ternary complex displaces a key helix within KSR, which derepresses its kinase activity<sup>38</sup>. Support for this allosteric activation mechanism was provided by evidence that the recruitment of the serine/threonine protein kinase BRAF substantially increases the kinase activity of KSR towards MEK. Experiments using a nucleotide-binding mutant of KSR that is specific for a particular synthetic ATP analogue confirmed that, in this case, MEK1 phosphorylation could only have been catalysed by KSR. Thus, small molecules that target the active conformation of KSR could have therapeutic benefit as potential modulators of the ERK cascade. Although more attention has focused on the complexity of RAF–KSR interfaces in the modulation of ERK signalling, other kinases are also indirectly recruited to this signalling unit. For example, the A-kinase anchor protein, AKAP-Lbc (also known as AKAP13), functions as an enhancer of ERK signalling by securing RAF in the vicinity of MEK1 and synchronizing the cAMP-dependent protein kinase A (PKA)-mediated phosphorylation of Ser838 on KSR<sup>39</sup>. This discovery not only offers mechanistic insight into the cAMP-responsive control of ERK signalling events but also shows how the coincident processing of discrete chemical signals can be integrated within this macromolecular complex.

Several recent reports show that MEK activation can occur through two separate mechanisms: either phosphorylation by BRAF in a complex with another RAF orthologue or phosphorylation by KSR (as described above)<sup>37,38,40</sup>. *In vitro* structure–function analyses and inhibitor studies have addressed these provocative findings. The introduction of a bulky phenylalanine residue within the ATP-binding pocket of KSR abolished nucleotide binding by KSR and the kinase activity of MEK<sup>40</sup>. Nevertheless, this KSR mutant retained its scaffold function, as it was able to bind to BRAF. Using an *in vitro* assay, it was shown that the catalytic activity of KSR persisted even with the addition of the RAF inhibitor sorafenib or the MEK inhibitor PD0325901 (REF. 38). However, other investigators have used these and other related compounds to determine an alternative mechanism to explain the effect of KSR on the ERK cascade<sup>37,41</sup>. More recently, this same group has shown that RAF dimers function in tandem, whereby one partner functions as an activator kinase that transmits activation signals to its binding partner, the receiver kinase<sup>42</sup>. These findings provide a potential explanation as to why changes in KSR expression alter the effects of some of the aforementioned RAF inhibitors on oncogenic RAS–ERK signalling. In the presence of activated RAS at the cell membrane, RAF inhibitors stabilize the side-by-side dimerization of BRAF and CRAF and thus ERK activation (FIG. 2b). However, independently of RAS or BRAF activation, RAF inhibitors promote the hetero dimerization of BRAF with KSR, which positions the associated MEK for phosphorylation<sup>37</sup>. In the absence of RAF inhibitors and RAS activation, the formation of KSR–BRAF dimers may function as a buffer to BRAF activation, as it competes with the CRAF–BRAF dimerization. Clearly, the RAF–MEK–ERK cascade can be activated through multiple pathways, and KSR has been functionally implicated as a participant with multiple roles — as a scaffold protein, a non-catalytic allosteric modulator, an active kinase and a facilitator of hetero-oligomerization. Irrespective of which of these functions of KSR predominates in an individual cellular context, it is clear

that the scaffold and pseudokinase protein KSR functions at pivotal points in the multiple activation routes of this MAPK pathway.

### Pseudophosphatases as scaffold proteins

The concept of pseudophosphatases originated from the realization that the second phosphotyrosine phosphatase domain of proteins such as CD45, RPTP $\gamma$  and RPTP $\zeta$  has little or no phosphatase activity against various *in vitro* sub-strates<sup>43,44</sup> (BOX 1). However, it was subsequently realized that pseudophosphatases also participate in substrate trapping<sup>45,46</sup>. Perhaps the best example of this is the serine/threonine/tyrosine-interacting protein (STYX), a catalytically inactive member of the dual-specificity phosphatase (DUSP) family<sup>47</sup> (FIG. 2c). One role for this bona fide pseudophosphatase is to compete with the active enzyme DUSP4 for binding to ERK1 and ERK2 in the nucleus (FIG. 2c). STYX also functions as a nuclear scaffold that traps elements of the ERK1 and ERK2 signalling cascade. Cellular and molecular modelling approaches have led to the proposal that depletion of STYX redirects ERK activity to the cytosol, where it can augment ERK-dependent fragmentation of the Golgi apparatus<sup>47</sup>. Thus, one way in which STYX and other pseudophosphatases seem to regulate signalling is by functioning as substrate traps that sequester phosphosubstrates.

As highlighted by numerous examples, the interaction of key signalling enzymes with pseudokinases and pseudophosphatases provides a mechanism for the fine-tuning of several kinase-signalling pathways. Similarly, other types of scaffold proteins that occupy pivotal positions within signalling networks are being investigated. The non-catalytic AKAPs are a classic example of this type of scaffold protein.

### AKAPs

Over the past 20 years, our understanding of AKAPs has grown from the discovery of a few simple binding proteins that were purported to direct PKA to specific subcellular locations, to a large family of multivalent enzyme scaffold proteins that organize complex signalling events<sup>48–53</sup>. Constraining broad-specificity enzymes, such as PKA, in customized macromolecular units enables cells to respond with efficiency and accuracy to the ebb and flow of diffusible second-messenger signals<sup>54</sup>. Most recently, various approaches have shown that AKAPs are dynamic participants in local signalling as a result of their flexibility in structure, transient interactions with other proteins and combinatorial assembly of binding partners<sup>55</sup> (FIG. 3).

### AKAPs tether PKA holoenzymes

A defining feature of AKAPs is their ability to associate with PKA holoenzymes, which are composed of two regulatory subunits and two catalytic subunits. Nuclear magnetic resonance spectroscopy and X-ray crystallography studies have shown that the regulatory type I (RI) or type II (RII) sub-units of PKA homodimerize to create a four-helix bundle that functions as a binding groove for AKAPs<sup>56–59</sup>. An amphipathic helix within the AKAP forms the reciprocal binding surface that binds to PKA with subnanomolar affinity<sup>60,61</sup>. Despite high-resolution structural information about this protein–protein interface, attempts by structural biologists to crystallize entire AKAP–PKA holoenzyme complexes have been

unsuccessful. One explanation could be that both proteins have recognized regions of structural disorder that are refractory to conventional structural biology approaches<sup>62,63</sup>. Thus, in conjunction with X-ray crystallography, alternative approaches — including protein mass spectrometry and single-particle fluorescence imaging — have been used to establish the composition, stoichiometry and architectural arrangement of selected AKAP complexes<sup>55</sup> (FIG. 3a – c). Recently, electron microscopy and 3D reconstructions of intact type II PKA–AKAP18 $\gamma$  complexes showed that they have a heteropentameric structure (consisting of one AKAP18 $\gamma$ , two PKA RII and two PKA catalytic sub-units) and can adopt a range of flexible tripartite configurations<sup>55</sup>. Intrinsically disordered regions within each PKA regulatory subunit impart the molecular plasticity that enables the associated catalytic subunits to have a radius of motion of  $\sim 16$  nm. One mechanistic implication of these structural analyses is that flexibility within the PKA complex could enable precise orientation of the anchored catalytic subunit towards substrates. Thus, AKAP can be thought of as a scaffolding catalyst that physically brings the reactants together, and the flexibility within the anchored PKA holoenzyme enables the precise orientation of the enzyme and substrate that is required for optimal reactivity.

### AKAP scaffolds in neuronal and endocrine pathways

Many biological insights into anchored signalling mechanisms have come from the investigation of human AKAP79 and its murine orthologue AKAP150, both of which are encoded by *AKAP5* (REF. 64). The members of this AKAP family (AKAP79/150) scaffold different combinations of protein kinases and phosphatases at the inner face of the plasma membrane, where they are positioned to respond to intracellular changes in the levels of second messengers, such as cAMP, Ca<sup>2+</sup> and phospholipids<sup>65–67</sup> (FIG. 3). An amphipathic helix on AKAP79/150 provides a binding site for PKA, a modified PIXIT motif on AKAP79/150 tethers the protein phosphatase 2B (PP2B; also known as calcineurin) heterodimer, and PKC interacts with AKAP79/150 in a phosphatidylserine-dependent manner through an amino-terminal basic and hydrophobic sequence (FIG. 3 b , c). Much work has focused on how different combinations of these AKAP79/150-anchored enzymes modulate transmembrane receptors and ion channels in neuronal, endocrine and muscle tissues.

Long-term potentiation (LTP) and long-term depression (LTD) are electrophysiological indices of synaptic transmission that are related to hippocampal learning and memory<sup>68</sup>. These phenomena are regulated in part through the phosphorylation of glutamate receptor 1 (GluR1; also known as GluA1), a subunit of the  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPA) for glutamate, which primes extrasynaptic receptors for synaptic insertion (FIG. 3d). Depletion of AKAP150 through siRNA in murine hippocampal neurons not only promotes mislocalization of PKA but also leads to reduced phosphorylation of GluR1 on Ser845 and the concomitant impairment of synaptic transmission and memory<sup>69,70</sup>. This model was further substantiated by analyses of AKAP150-knockout mice, in which displacement of both PKA and PP2B from postsynaptic sites altered hippocampal synaptic transmission. These studies were extended in PP2B–anchoring-deficient AKAP150 PP2B knock-in mice, in which the LTD-induced dephosphorylation and displacement of AMPAR and the AKAP150 signalling complex

from the synapse were impaired<sup>70</sup>. Thus, it is clear that in these cells the AKAP150-anchored PP2B counterbalances the phosphorylation of GluR1 by the anchored PKA to control synaptic plasticity.

In sympathetic cervical ganglion neurons, loss of AKAP150 reduces muscarinic acetylcholine receptor-mediated suppression of inhibitory M currents through M channels<sup>71</sup>. These ion channels generate an outward potassium current that is required for the firing of an action potential. This process is thought to occur through the AKAP-mediated targeting of PKC to the KCNQ2 subunit of the M channel, the phosphorylation of which inhibits potassium permeability to enhance neuronal excitability<sup>67,72</sup>. Paradoxically, loss of this vital sympathetic neuronal response affords AKAP150-knockout mice some protection from seizures induced by the muscarinic agonist pilocarpine<sup>73</sup>. A secondary discovery that may be related to this phenomenon is that binding to AKAP150 rendered PKC insensitive to the ATP-competitive inhibitor bisindolylmaleimide I<sup>74</sup>. This unforeseen observation indicated that AKAP79 and AKAP150 not only control the access of binding partners to their substrates but also influence how binding partners such as PKC respond to certain pharmacological inhibitors. A broader interpretation of this result is that scaffold proteins such as AKAPs also function as allosteric modifiers that shape the activity of the kinase or phosphatase under their control. This may have important implications for drug discovery and research projects predicated on the selectivity of pharmacological protein kinase inhibitors.

In pancreatic  $\beta$ -islets, AKAP150 directs cAMP-dependent PKA and  $\text{Ca}^{2+}$ /calmodulin-dependent PP2B towards elements of the insulin release machinery that are controlled by changes in cAMP and  $\text{Ca}^{2+}$  levels. The scaffold protein AKAP150 directly binds to the cytoplasmic tail of L-type  $\text{Ca}^{2+}$  channels, where the associated enzymes (PKA and PP2B) control the phosphorylation-dependent modulation of channel activity. Loss of AKAP150 suppresses the activity of the  $\text{Ca}^{2+}$  channels, and the disrupted  $\text{Ca}^{2+}$  influx in these cells is accompanied by perturbation of the submembrane oscillations of cAMP levels that are crucial for insulin release<sup>75,76</sup>. This result may also be indicative of the compromised modulation of AKAP150-associated  $\text{Ca}^{2+}$ -sensitive adenylyl cyclases that generate cAMP and that are under the control of other enzymes within the AKAP150 complex<sup>77,78</sup>. An important new concept that has arisen from these studies is that decreased insulin release from AKAP150-deficient islets is not a consequence of interrupted signalling at a single intracellular locus but rather the result of a multifaceted failure of discrete molecular events at vulnerable points in the secretory cascade that are normally coordinated by the AKAP scaffold<sup>79</sup>.

A logical consequence of reduced insulin release from  $\beta$ -islets is impaired glucose tolerance but, unexpectedly, AKAP150-knockout mice have improved glucose handling<sup>79</sup>. This confounding but metabolically favourable phenotype could be explained by one of two phenomena: a compensatory reduction in the level of the counter-regulatory hormone glucagon (which controls the release of stored glycogen), or enhanced insulin sensitivity. Metabolic profiling of AKAP150-deficient mice showed that compensatory mechanisms, such as reduced glycogen mobilization, do not contribute to their improved glucose tolerance. However, metabolic profiling of PP2B-anchoring-deficient AKAP150 PP2B

knock-in mice provided an intriguing observation: deletion of seven amino acids (PIAIIIT) from AKAP150 not only disrupted PP2B targeting *in vivo* but also enhanced insulin sensitivity in skeletal muscle and the liver<sup>79</sup>(FIG. 3e). Therefore, small molecules that perturb the tethering of the phosphatase PP2B to AKAP150 might boost insulin sensitivity. Such a therapeutic approach could be of particular value to recipients of organ transplants who require immunosuppressive phosphatase-inhibitor drugs, such as cyclosporin and FK506. One drawback is that these drugs have considerable adverse effects, including increased blood glucose levels and hypertension, which are hallmarks of a newly defined clinical syndrome known as new-onset diabetes after transplant. Hence, compounds that target anchored PP2B to boost insulin action in peripheral tissues could be used in combination with immunosuppressive drugs to restore glucose homeostasis in these patients.

Although AKAPs have no intrinsic enzymatic activity themselves, it is their complement of associated enzymes that determines the function of the scaffold. Moreover, as mentioned above, several recent studies suggest that AKAPs allosterically modulate the enzymatic activity of their binding partners. Consequently, within AKAP– enzyme scaffolds there are multiple protein interfaces that could be examined as potential therapeutic targets for the disruption of pathological signalling.

### Signal termination scaffolds

Enzymes that inactivate substrates or promote the degradation of key elements in signalling pathways often function as ‘off ‘ switches. Similarly to signal activation mechanisms, these homeostatic mechanisms are also more effective when organized into protein scaffolds. Three examples of this are the scaffolds that target phosphatases, those that control protein ubiquitylation and those that control acetylation and deacetylation (FIG. 4).

### Phosphatase scaffolds

Generally, the greater catalytic efficiency of phosphoprotein phosphatases affords them a competitive advantage over their kinase counterparts. Consequently, the dephosphorylation of substrates often predominates when phosphatases are recruited to kinase-containing scaffolds. The targeting of some phosphatases may be quite simple, whereas others are constrained within larger signalling scaffolds. The regulatory phosphatase subunits PP2A, PP4 and PP6 have been shown to restrict their respective catalytic subunits to defined subcellular locations, where the catalytic sub-units dephosphorylate a subset of nearby substrates<sup>80–82</sup>. However, our understanding of how PP1 is directed towards its substrates is much more complete. More than 200 PP1-interacting proteins have been identified that scaffold specific protein complexes with the phosphatase catalytic subunit (PP1c) to modulate all aspects of PP1 action<sup>83</sup>. Subcellular targeting is mediated by a short conserved binding motif (RVxF or variants) in the scaffold protein, often preceded by further basic residues, which docks on a small hydrophobic groove surface on PP1 (REFS 25,84) (FIG. 4a). Another key facet of PP1 scaffolding is that the association of PP1 with targeting subunits allosterically modulates enzymatic activity and determines substrate specificity, as first demonstrated for the glycogen-targeting subunit G<sub>M</sub> and glycogen-associated phosphosubstrates<sup>85</sup>. Accordingly, these PP1 interactions determine the regulation of diverse cellular events, such as the onset of hypertension and tumour growth.



The myosin light-chain phosphatase complex controls the dephosphorylation of proteins to promote the relaxation of smooth muscle in arterial walls<sup>86,87</sup>. Myosin light-chain phosphatase is a desirable therapeutic target for the management of hypertension, as drugs that can reduce vascular tone will ultimately normalize blood pressure. Current interest in myosin light-chain phosphatase centres on the modulation of its PP1-targeting subunit, MYPT1 (also known as PPP1R12A)<sup>88,89</sup>. Mobilization of the nitric oxide (NO) pathway — either naturally or pharmacologically with nitrovasodilators — produces the second messenger cGMP (FIG. 4b). This leads to the activation of PKG, another component of the myosin light-chain phosphatase complex<sup>88</sup>. PKG-mediated phosphorylation of MYPT1 activates PP1 to promote rapid smooth muscle relaxation through myosin light chain dephosphorylation. By contrast, phosphorylation of the MYPT1 scaffold protein by the RHO-associated protein kinase 1 (ROCK1) inhibits myosin light-chain dephosphorylation<sup>90,91</sup>. Thus, combining nitrovasodilators with ROCK1 inhibitors to manage smooth muscle contraction is being considered for the treatment of hypertension.

MAPK cascades comprising RAF–MEK–ERK transmit signals from growth factors to cell proliferation through mobilization of the GTPase RAS<sup>92</sup>. Interest in this signalling pathway is motivated by clinical evidence that activating mutations in *RAS* are found in ~30% of human tumours<sup>93</sup>. In addition, several ‘RASopathies’ have been identified. One of these disorders, a Noonan-like syndrome with loose anagen hair, is caused by a mutation in the gene encoding the phosphatase-targeting protein SHOC2 that results in aberrant targeting of SHOC2 (REF. 94). Recent evidence indicates that SHOC2 requires interaction with the RAS-related GTP-binding protein MRAS for high-affinity binding to PP1c and the subsequent dephosphorylation of an inhibitory site on RAF<sup>95,96</sup>. One unusual feature of the SHOC2–PP1 scaffold is the recruitment of an additional PP1-interacting protein, SCRIB (FIG. 4c). Formation of this larger complex, which contains multiple phosphatase-targeting components, promotes internal competition between SHOC2 and SCRIB for PP1c binding, thus controlling the phosphorylation and activation of RAF<sup>95</sup>. This complicated PP1-dependent mechanism has been postulated to fine-tune the frequency and amplitude of ERK activity pulses during the establishment of cell polarity<sup>95</sup>.

### Ubiquitylation scaffolds

It is well known that protein ubiquitylation regulates protein degradation and enables the control of protein quality — a cellular phenomenon in which damaged or inappropriately folded proteins are eliminated<sup>97</sup>. However, ubiquitylation is also an effective means of modifying protein-protein interactions<sup>98</sup>. Accordingly, ubiquitylation is increasingly being recognized as a dynamic modulator of molecular scaffolds<sup>99</sup>. Nowhere are these roles more relevant than in the nucleus, where the integrity of nuclear proteins is essential for transcriptional fidelity and cell division<sup>97</sup>. In yeast, the nuclear E3 ligase San1 is a highly selective sensor that can discriminate between folded and misfolded forms of the same protein<sup>100</sup>. Although San1 is a bona fide RING-finger E3 ligase, it also functions as a scaffold protein (FIG. 4d). Flexible and intrinsically disordered regions of San1 confer a plasticity that enables this enzyme to recognize, bind to, ubiquitylate and thereby signal the removal of a diverse collection of misfolded substrates<sup>101</sup>.

During the mammalian cell cycle, cullin-RING ligase (CRL) functions as a molecular scaffold that brings together one of several RING-finger proteins (RBX1, RBX2 or RO52 (also known as TRIM21)) plus its active component, a specific ubiquitin-conjugating enzyme (UBC), and the adaptor S phase kinase-associated protein 1 (SKP1), which binds to an F-box protein (SKP2) and its associated substrate<sup>102</sup>. These scaffolds direct the UBC towards an appropriate cyclin-dependent kinase (CDK) inhibitor to target it for ubiquitylation and degradation. Thus, by using interchangeable F-box, RING-finger and UBC proteins, an individual SKP1-cullin 1 (CUL1)-F-box protein complex can be tailored for cell cycle progression.

### Acetylation scaffolds

Reversible protein acetylation has emerged as a versatile form of post-translational modification, the importance of which rivals phosphorylation and ubiquitylation. This process is controlled by the opposing actions of acetyltransferases and deacetylases. In the nucleus, histone acetyltransferases (HATs) are frequently associated with transcriptional activation, whereas histone deacetylases (HDACs) are often linked to the inactivation of genes. The formation of a larger scaffold that can simultaneously target HATs and HDACs within the same complex has been shown to sustain transcriptional competence during myogenesis and transcriptional events that proceed through the tumour suppressor p53 (REF. 103). Higher-order HAT complexes can also control nucleosome remodelling<sup>104</sup>. Of particular interest are larger macromolecular scaffolds that contain protein kinases as well as acetyltransferases<sup>105</sup>. For example, the ADA2-containing (ATAC) HAT complex constrains a three-tier JUN kinase cascade in proximity to target genes. In this context, the ATAC complex functions as both a transcriptional co-activator of and a scaffold for JUN N-terminal kinase (JNK) signalling<sup>105</sup>. The integration of these signalling enzymes within the ATAC scaffold facilitates a timely response to osmotic stress.

Recent evidence also suggests that, in the cytoplasm, phosphoenolpyruvate carboxykinase 1 (PEPCK1) functions as a scaffold for the acetylation and deacetylation enzymes that regulate PEPCK1 activity in response to blood glucose levels<sup>106</sup>. Acetylation of PEPCK1 by the acetyltransferase p300 in the complex promotes recruitment of the E3 ubiquitin ligase UBR5 and proteasomal degradation of PEPCK1 (FIG. 4e). The deacetylase sirtuin 2 (SIRT2) that is contained within the complex counteracts this process to prolong the half-life of PEPCK1. Interestingly, this homeostatic process is regulated by the metabolic state of the cell. High glucose levels induce the expression of p300 and suppress SIRT2 activity, which favours the acetylation and degradation of PEPCK1. However, under low-glucose conditions, SIRT2-mediated deacetylation stabilizes PEPCK1 to drive gluconeogenesis (FIG. 4e). Thus, it has been postulated that controlling the acetylation status and half-life of PEPCK1 has the potential to manage aspects of diabetes and metabolic syndrome<sup>106</sup>. In a broader context, proteomic studies have shown that the acetylation profile and stability of proteins can be quite different in many cell types, including liver and leukaemia cells<sup>107–109</sup>. Thus, scaffolded acetyltransferase- and deacetylase-mediated regulatory circuits that control the half-life of the transcriptional machinery or of metabolic enzymes may prove to be therapeutic targets for the management of metabolic disorders and certain cancers.

The above examples are just a few of the protein scaffolds that incorporate signal termination enzymes within their repertoire of binding proteins. In the following section, we discuss recent studies that have identified other scaffold proteins that are able to rapidly toggle between on and off signals in response to the rapidly changing intracellular environment.

## The switch function of scaffold proteins

By constraining successive enzymes in a signalling cascade, scaffold proteins simultaneously facilitate the efficient relay of chemical messages and segregate individual signalling units for the accurate processing of molecular information. These macromolecular assemblies have also been shown to enhance enzymatic activity and to identify and mark proteins for degradation. However, an emerging role for some of these scaffold proteins is as ultra-sensitive switches that determine alternative cell fates. New discoveries regarding two prototypical MAPK scaffolds underlie this new perspective.

In yeast, pheromone-induced recruitment of the sterile 5 gene product (Ste5) to the plasma membrane promotes its active conformation<sup>110,111</sup>. This induces binding of all three members of a MAPK cascade (the MEKK Ste11, the MEK Ste7 and the MAPK Fus3) to propagate the mating response<sup>112</sup> (FIG. 5a). However, at certain stages of the cell cycle, this constellation of enzymes can have other biological effects. Phosphorylation of the scaffold protein Ste5 by the cell cycle regulator kinase Cdk blocks accumulation of Ste5 at the cell membrane<sup>113</sup>. Recent advances in synthetic biology, combined with structural studies, indicate that conformational changes in Ste5 enable the constrained MAPK complex to switch between alternative fates<sup>114,115</sup> (FIG. 5a). For example, recruitment of Fus3 to another binding site on Ste5 mediates feedback phosphorylation events that initiate a yeast morphological response known as 'shmooing', in which opposite mating types of haploid yeast cells migrate towards each other in order to fuse and form a diploid cell<sup>113</sup>.

In mammals, the JNK-interacting protein (JIP) family coordinates three-tier JNK and p38 MAPK modules<sup>116</sup>. JIPs were initially identified as elements that contribute to glutamate transporter type 2 gene expression and  $\beta$ -cell function, but members of this scaffold protein family can also oligomerize to create pockets of concentrated kinase activity<sup>117</sup>. In highly polarized cells such as neurons, JIP1 has a unique role in the directional movement of its cargo of signalling enzymes along microtubules (FIG. 5b). This is accomplished through association with kinesin motor proteins that move towards the plus end of growing microtubules or with dynactins that track towards the minus end of microtubules<sup>118</sup>. Moreover, JIP1 can also interact with the dual-specificity phosphatases MKP7 (also known as DUSP16) and M3/6 to switch off the JNK activation module<sup>119</sup>. More recent evidence suggests that JIP1 co-ordinates the retrograde axonal transport of autophagosomes. During neuronal development, these organelles deliver cytoplasmic materials from the growth cone to the cell body, where they are degraded by lysosomes<sup>120</sup>. Phosphorylation of JIP1 on Ser421 increases binding to kinesin, whereas dephosphorylation favours binding to dynactin<sup>120</sup>. Thus, covalent modification of this scaffold protein not only determines which binding partners preferentially associate with JIP1 but also switches the directional movement of this organellar signalling scaffold (FIG. 5b).

## Conclusions and future directions

As discussed above, scaffold proteins regulate a multitude of cellular responses — at the plasma membrane, on organelles and in the nucleus. They coordinate enzyme location and activation, and substrate selectivity. They also function as allosteric modulators of the enzymes under their influence, facilitate the transport of cargo and segregate alternative cellular fates. Consequently, they are prime research targets for therapeutic objectives.

Emergent technologies often open the door to new biological insights. In this final section, we highlight three biophysical applications that provide the means to establish the stoichiometry of enzyme scaffolds, the range of enzyme combinations assembled on an individual scaffold protein and the near-atomic structural details of intact macromolecular complexes (FIG. 6).

First, native mass spectrometry is an exciting new technique that probes the quaternary structure of intact protein complexes that are suspended in volatile buffers<sup>121,122</sup>. This powerful quantitative approach can accurately establish the composition and stoichiometry of macromolecular complexes<sup>123</sup>. Native mass spectrometry can even be used to monitor the binding of a drug to different configurations of a signalling scaffold and to establish whether the complex under investigation exists in multimeric forms (FIG. 6a – c).

Second, single-molecule pull-down photobleaching (SiMPull) is an exquisitely sensitive pull-down assay that monitors the number of sequential photo bleaching steps to accurately calculate the stoichiometry of the individual fluorescent enzyme–scaffold complexes that are captured from cell lysates<sup>124</sup>. This approach has been successfully used to calculate the stoichiometry of several PKA–AKAP complexes *in situ*<sup>125</sup>. Another innovative modification of the SiMPull technique monitors two proteins labelled with different fluorophores. This has been used to calculate the occupancy of the enzyme-binding site on a scaffold protein (FIG. 6d,e).

Third, the complexity, size and intrinsic disorder of many macromolecular complexes preclude analysis by X-ray crystallography<sup>62</sup>. The cutting-edge approaches of negative-stain electron microscopy and cryo-electron microscopy can be applied to resolve near-atomic structures of enzyme scaffolds (FIG. 6f,g). Moreover, recent innovations in detection sensors and processing algorithms have enabled the collection and analysis of cryo-electron microscopy data sets that extend the effective resolution of reconstructed macromolecular assemblies to a resolution of  $<4 \text{ \AA}$ <sup>126–130</sup>. This level of resolution produces density maps that will enable investigators to pinpoint the conformational elements of these large and flexible signalling scaffolds that are crucial for their function. Undoubtedly, the increasing use of these three technical breakthroughs will yield new insights into the inner workings of enzyme scaffolds as local mediators of cellular control.

## Acknowledgments

The authors apologize to all colleagues whose work has not been cited owing to space limitations. The authors thank F. D. Smith for providing the negative-stain electron microscopy images presented in Figure 4f, and members of the Scott Lab for discussions. Support for this work was provided by the US National Institutes of Health (NIH) grants DK105542 and DK054441, and the Howard Hughes Medical Institute.

## Glossary

<b>Allosteric modulators</b>	Proteins that bind to a site that is distinct from the orthosteric agonist-binding site. They usually induce a conformational change within the protein structure
<b>Long-term potentiation (LTP)</b>	A process whereby brief periods of synaptic activity can produce a long-lasting increase in the strength of a neuronal synapse. LTP has an important role in learning and memory
<b>Long-term depression (LTD)</b>	A long-lasting decrease in the synaptic response of neurons to stimulation of their afferents following a long patterned stimulus
<b>M channels</b>	Muscarinic receptor-sensitive potassium channels that coordinate the depolarization of neurons and prepare these cells for the next action potential
<b>L-type Ca<sup>2+</sup> channels</b>	Ion channels that control Ca <sup>2+</sup> influx into a large number of cell types. They are one of the most studied types of ion channels

## References

1. Sadowski I, Stone JC, Pawson T. A non-catalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. *Mol. Cell. Biol.* 1986; 6:4396–4408. [PubMed: 3025655]
2. Pawson T. Protein modules and signalling networks. *Nature.* 1995; 373:573–580. [PubMed: 7531822]
3. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell.* 2010; 141:1117–1134. [PubMed: 20602996]
4. Songyang Z, Cantley LC. Recognition and specificity in protein tyrosine kinase-mediated signalling. *Trends Biochem. Sci.* 1995; 20:470–475. [PubMed: 8578591]
5. Good MC, Zalatan JG, Lim WA. Scaffold proteins: hubs for controlling the flow of cellular information. *Science.* 2011; 332:680–686. [PubMed: 21551057]
6. Shaw AS, Kornev AP, Hu J, Ahuja LG, Taylor SS. Kinases and pseudokinases: lessons from RAF. *Mol. Cell. Biol.* 2014; 34:1538–1546. [PubMed: 24567368]
7. Fields S, Song O. A novel genetic system to detect protein-protein interactions. *Nature.* 1989; 340:245–246. [PubMed: 2547163]
8. Aebersold R, Mann M. Mass spectrometry-based proteomics. *Nature.* 2003; 422:198–207. [PubMed: 12634793]
9. Bowtell DD, Simon MA, Rubin GM. Ommatidia in the developing *Drosophila* eye require and can respond to sevenless for only a restricted period. *Cell.* 1989; 56:931–936. [PubMed: 2924353]
10. Simon MA, Bowtell DD, Dodson GS, Laverly TR, Rubin GM. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. *Cell.* 1991; 67:701–716. [PubMed: 1934068]
11. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. *Cell.* 2007; 128:225–231. [PubMed: 17254958]
12. Pawson T, Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. *Science.* 1997; 278:2075–2080. [PubMed: 9405336]
13. Dodge-Kafka KL, Langeberg L, Scott JD. Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. *Circ. Res.* 2006; 98:993–1001. [PubMed: 16645149]
14. Scott JD, Pawson T. Cell communication: the inside story. *Sci. Am.* 2000; 282:72–79. [PubMed: 10862426]

15. Lowenstein EJ, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. *Cell*. 1992; 70:431–442. [PubMed: 1322798]
16. Pelicci G, et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. *Cell*. 1992; 70:93–104. [PubMed: 1623525]
17. Sun XJ, Crimmins DL, Myers MGJ, Miralpeix M, White MF. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. *Mol. Cell. Biol.* 1993; 13:7418–7428. [PubMed: 7504175]
18. Wolf G, et al. PTB domains of IRS-1 and Shc have distinct but overlapping binding specificities. *J. Biol. Chem.* 1995; 270:27407–27410. [PubMed: 7499194]
19. Kouhara H, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. *Cell*. 1997; 89:693–702. [PubMed: 9182757]
20. Bhattacharyya RP, Remenyi A, Yeh BJ, Lim WA. Domains, motifs, and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. *Annu. Rev. Biochem.* 2006; 75:655–680. [PubMed: 16756506]
21. Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when they're apart. *Science*. 2009; 326:1220–1224. [PubMed: 19965465]
22. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. *Trends Cell Biol.* 2006; 16:443–452. [PubMed: 16879967]
23. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science*. 2002; 298:1912–1934. [PubMed: 12471243]
24. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. *Trends Biochem. Sci.* 2002; 27:514–520. [PubMed: 12368087]
25. Egloff MP, et al. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. *EMBO J.* 1997; 16:1876–1887. [PubMed: 9155014]
26. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. *Cell*. 1997; 90:859–869. [PubMed: 9298898]
27. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. *Mol. Syst. Biol.* 2005; 1 2005.0008.
28. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. *Cell*. 2006; 125:1137–1149. [PubMed: 16777603]
29. Hemminki A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature*. 1998; 391:184–187. [PubMed: 9428765]
30. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. *Acta Physiol.* 2009; 196:65–80.
31. Zheng B, Cantley LC. Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. *Proc. Natl Acad. Sci. USA.* 2007; 104:819–822. [PubMed: 17204563]
32. Boudeau J, et al. MO25 $\alpha/\beta$  interact with STRAD $\alpha/\beta$  enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. *EMBO J.* 2003; 22:5102–5114. [PubMed: 14517248]
33. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM. Structure of the LKB1-STRAD - MO25 complex reveals an allosteric mechanism of kinase activation. *Science*. 2009; 326:1707–1711. [PubMed: 19892943] This elegant structural study shows how conformational changes induced by protein-protein interactions within the LKB1-STRAD-MO25 scaffold lead to activation of the kinase LKB1
34. Rajakulendran T, Sicheri F. Allosteric protein kinase regulation by pseudokinases: insights from STRAD. *Sci. Signal.* 2010; 3:pe8. [PubMed: 20197543]
35. Zeqiraj E, et al. ATP and MO25 $\alpha$  regulate the conformational state of the STRAD $\alpha$  pseudokinase and activation of the LKB1 tumour suppressor. *PLoS Biol.* 2009; 7:e1000126. [PubMed: 19513107]
36. Morrison DK. KSR: a MAPK scaffold of the Ras pathway? *J. Cell Sci.* 2001; 114:1609–1612. [PubMed: 11309192]
37. McKay MM, Ritt DA, Morrison DK. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. *Curr. Biol.* 2011; 21:563–568. [PubMed: 21458265]

38. Brennan DF, et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. *Nature*. 2011; 472:366–369. [PubMed: 21441910] References 37 and 38 are representative of several papers that reveal different mechanistic aspects of KSR action
39. Smith FD, et al. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. *Nature Cell Biol*. 2010; 12:1242–1249. [PubMed: 21102438]
40. Hu J, et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. *Proc. Natl Acad. Sci. USA*. 2011; 108:6067–6072. [PubMed: 21441104]
41. Poulidakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. *Nature*. 2010; 464:427–430. [PubMed: 20179705]
42. Hu J, et al. Allosteric activation of functionally asymmetric RAF kinase dimers. *Cell*. 2013; 154:1036–1046. [PubMed: 23993095]
43. Wishart MJ, Denu JM, Williams JA, Dixon JE. A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. *J. Biol. Chem*. 1995; 270:26782–26785. [PubMed: 7592916]
44. Tonks NK. Pseudophosphatases: grab and hold on. *Cell*. 2009; 139:464–465. [PubMed: 19879835]
45. Cheng KC, Klancer R, Singson A, Seydoux G. Regulation of MBK-2/DYRK by CDK-1 and the pseudophosphatases EGG-4 and EGG-5 during the oocyte-to-embryo transition. *Cell*. 2009; 139:560–572. [PubMed: 19879842] This study describes one of the first examples of a pseudophosphatase functioning as a conformational clamp to recruit substrates
46. Parry JM, et al. EGG-4 and EGG-5 link events of the oocyte-to-embryo transition with meiotic progression in *C. elegans*. *Curr. Biol*. 2009; 19:1752–1757. [PubMed: 19879147]
47. Reiterer V, Fey D, Kolch W, Kholodenko BN, Farhan H. Pseudophosphatase STYX modulates cell-fate decisions and cell migration by spatiotemporal regulation of ERK1/2. *Proc. Natl Acad. Sci. USA*. 2013; 110:E2934–E2943. [PubMed: 23847209] This paper shows an example of STYX function in a well-defined cellular context
48. Scott JD, et al. Type II regulatory subunit dimerization determines the subcellular localization of the cAMP-dependent protein kinase. *J. Biol. Chem*. 1990; 265:21561–21566. [PubMed: 2147685]
49. Luo Z, Shafit-Zagardo B, Erlichman J. Identification of the MAP2- and P75- binding domain in the regulatory subunit (RII $\beta$ ) of type II cAMP-dependent protein kinase. *J. Biol. Chem*. 1990; 265:21804–21810. [PubMed: 2254332]
50. Carr DW, et al. Interaction of the regulatory subunit (RII) of cAMP-dependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. *J. Biol. Chem*. 1991; 266:14188–14192. [PubMed: 1860836]
51. Rubin CS. A kinase anchor proteins and the intracellular targeting of signals carried by cAMP. *Biochim. Biophys. Acta*. 1994; 1224:467–479. [PubMed: 7803506]
52. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. *Physiol. Rev*. 2004; 84:137–167. [PubMed: 14715913]
53. Welch EJ, Jones BW, Scott JD. Networking with AKAPs: context-dependent regulation of anchored enzymes. *Mol. Interv*. 2010; 10:86–97. [PubMed: 20368369]
54. Wong W, Scott JD. AKAP signalling complexes: focal points in space and time. *Nature Rev. Mol. Cell Biol*. 2004; 5:959–971. [PubMed: 15573134]
55. Smith FD, et al. Intrinsic disorder within an AKAP-protein kinase A complex guides local substrate phosphorylation. *eLife*. 2013; 2:e01319. [PubMed: 24192038] This paper contains the first description of the structure of an intact anchored PKA holoenzyme. This study also highlights the utility of intrinsic disorder as a means to manage substrate specificity
56. Newlon MG, et al. The molecular basis for protein kinase A anchoring revealed by solution NMR. *Nature Struct. Biol*. 1999; 6:222–227. [PubMed: 10074940]
57. Gold MG, et al. Molecular basis of AKAP specificity for PKA regulatory subunits. *Mol. Cell*. 2006; 24:383–395. [PubMed: 17081989]
58. Kinderman FS, et al. A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. *Mol. Cell*. 2006; 24:397–408. [PubMed: 17081990]


59. Sarma GN, et al. Structure of D-AKAP2:PKA RI complex: insights into AKAP specificity and selectivity. *Structure*. 2010; 18:155–166. [PubMed: 20159461]
60. Carr DW, Hausken ZE, Fraser ID, Stofko-Hahn RE, Scott JD. Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein Cloning and characterization of the RII-binding domain. *J. Biol. Chem.* 1992; 267:13376–13382. [PubMed: 1618839]
61. Lester LB, Coghlan VM, Nauert B, Scott JD. Cloning and characterization of a novel A-kinase anchoring protein: AKAP220, association with testicular peroxisomes. *J. Biol. Chem.* 1996; 272:9460–9465. [PubMed: 8621616]
62. Gao S, Wang HY, Malbon CC. AKAP12 and AKAP5 form higher-order hetero-oligomers. *J. Mol. Signal.* 2011; 6:8. [PubMed: 21831305]
63. Gold MG, et al. Engineering A-kinase anchoring protein (AKAP)-selective regulatory subunits of protein kinase A (PKA) through structure-based phage selection. *J. Biol. Chem.* 2013; 288:17111–17121. [PubMed: 23625929]
64. Carr DW, Stofko-Hahn RE, Fraser IDC, Cone RD, Scott JD. Localization of the cAMP-dependent protein kinase to the postsynaptic densities by A-kinase anchoring proteins: characterization of AKAP79. *J. Biol. Chem.* 1992; 24:16816–16823. [PubMed: 1512224]
65. Coghlan VM, et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. *Science*. 1995; 267:108–112. [PubMed: 7528941]
66. Klauk TM, et al. Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. *Science*. 1996; 271:1589–1592. [PubMed: 8599116]
67. Hoshi N, Langeberg LK, Scott JD. Distinct enzyme combinations in AKAP signalling complexes permit functional diversity. *Nature Cell Biol.* 2005; 7:1066–1073. [PubMed: 16228013]
68. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. *Neuron*. 2013; 80:704–717. [PubMed: 24183021]
69. Tavalin SJ, et al. Regulation of GluR1 by the A-kinase anchoring protein 79 (AKAP79) signaling complex shares properties with long-term depression. *J. Neurosci.* 2002; 22:3044–3051. [PubMed: 11943807]
70. Sanderson JL, et al. AKAP150-anchored calcineurin regulates synaptic plasticity by limiting synaptic incorporation of Ca<sup>2+</sup>-permeable AMPA receptors. *J. Neurosci.* 2012; 32:15036–15052. [PubMed: 23100425] This paper provides compelling evidence that AKAP150-anchored PP2B is a dominant effector in the modulation of synaptic transmission
71. Suh BC, Inoue T, Meyer T, Hille B. Rapid chemically induced changes of PtdIns(4,5)P<sub>2</sub> gate KCNQ ion channels. *Science*. 2006; 314:1454–1457. [PubMed: 16990515]
72. Hoshi N, et al. AKAP150 signaling complex promotes suppression of the M-current by muscarinic agonists. *Nature Neurosci.* 2003; 6:564–571. [PubMed: 12754513]
73. Tunquist BJ, et al. Loss of AKAP150 perturbs distinct neuronal processes in mice. *Proc. Natl Acad. Sci. USA.* 2008; 105:12557–12562. [PubMed: 18711127]
74. Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD. Interaction with AKAP79 modifies the cellular pharmacology of PKC. *Mol. Cell.* 2010; 37:541–550. [PubMed: 20188672] Using a combination of biochemistry and live-cell imaging, these authors demonstrate that selected ATP-directed kinase inhibitor drugs are refractory to their targets when the enzymes are located in AKAP complexes
75. Dyachok O, Isakov Y, Sagetorp J, Tengholm A. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting  $\beta$ -cells. *Nature*. 2006; 439:349–352. [PubMed: 16421574]
76. Lester LB, Faux MC, Nauert JB, Scott JD. Targeted protein kinase A and PP-2B regulate insulin secretion through reversible phosphorylation. *Endocrinology*. 2001; 142:1218–1227. [PubMed: 11181538]
77. Bauman AL, et al. Dynamic regulation of cAMP synthesis through anchored PKA-adenylyl cyclase V/VI complexes. *Mol. Cell.* 2006; 23:925–931. [PubMed: 16973443]
78. Dessauer CW. Adenylyl cyclase — A-kinase anchoring protein complexes: the next dimension in cAMP signaling. *Mol. Pharmacol.* 2009; 76:935–941. [PubMed: 19684092]
79. Hinke SA, et al. Anchored phosphatases modulate glucose homeostasis. *EMBO J.* 2012; 31:3991–4004. [PubMed: 22940692]



80. Cohen P. The origins of protein phosphorylation. *Nature Cell Biol.* 2002; 4:E127–E130. [PubMed: 11988757]
81. Cohen PT. Protein phosphatase 1 — targeted in many directions. *J. Cell Sci.* 2002; 115:241–256. [PubMed: 11839776]
82. Vazquez-Martin C, Rouse J, Cohen PT. Characterization of the role of a trimeric protein phosphatase complex in recovery from cisplatin-induced versus noncrosslinking DNA damage. *FEBS J.* 2008; 275:4211–4221. [PubMed: 18647348]
83. Bollen M. Combinatorial control of protein phosphatase-1. *Trends Biochem. Sci.* 2001; 26:426–431. [PubMed: 11440854]
84. Hendrickx A, et al. Docking motif-guided mapping of the interactome of protein phosphatase-1. *Chem. Biol.* 2009; 16:365–371. [PubMed: 19389623]
85. De Munter S, Kohn M, Bollen M. Challenges and opportunities in the development of protein phosphatase-directed therapeutics. *ACS Chem. Biol.* 2013; 8:36–45. [PubMed: 23214403]
86. Hartshorne DJ, Hirano K. Interactions of protein phosphatase type 1, with a focus on myosin phosphatase. *Mol. Cell. Biochem.* 1999; 190:79–84. [PubMed: 10098973]
87. Surks HK, et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I $\alpha$ . *Science.* 1999; 286:1583–1587. [PubMed: 10567269]
88. Lincoln TM. Myosin phosphatase regulatory pathways: different functions or redundant functions? *Circ. Res.* 2007; 100:10–12. [PubMed: 17204659]
89. Matsumura F, Hartshorne DJ. Myosin phosphatase target subunit: many roles in cell function. *Biochem. Biophys. Res. Commun.* 2008; 369:149–156. [PubMed: 18155661]
90. Lee MR, Li L, Kitazawa T. Cyclic GMP causes Ca<sup>2+</sup> desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. *J. Biol. Chem.* 1997; 272:5063–5068. [PubMed: 9030570]
91. Kaneko-Kawano T, et al. Dynamic regulation of myosin light chain phosphorylation by Rho-kinase. *PLoS ONE.* 2012; 7:e39269. [PubMed: 22723981]
92. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. *Oncogene.* 2007; 26:3113–3121. [PubMed: 17496910]
93. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. *Nature Rev. Cancer.* 2003; 3:459–465. [PubMed: 12778136]
94. Cordeddu V, et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. *Nature Genet.* 2009; 41:1022–1026. [PubMed: 19684605]
95. Young LC, et al. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. *Mol. Cell.* 2013; 52:679–692. [PubMed: 24211266] This study provides evidence that, in the context of some macromolecular scaffolds, rival targeting subunits compete for PP1 binding.
96. Rodriguez-Viciano P, Oses-Prieto J, Burlingame A, Fried M, McCormick F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. *Mol. Cell.* 2006; 22:217–230. [PubMed: 16630891]
97. Wolff S, Weissman JS, Dillin A. Differential scales of protein quality control. *Cell.* 2014; 157:52–64. [PubMed: 24679526]
98. Grabbe C, Dikic I. Cell biology Going global on ubiquitin. *Science.* 2008; 322:872–873. [PubMed: 18988833]
99. Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. *Cell. Death Differ.* 2013; 20:21–30. [PubMed: 22722335]
100. Gardner RG, Nelson ZW, Gottschling DE. Degradation-mediated protein quality control in the nucleus. *Cell.* 2005; 120:803–815. [PubMed: 15797381] This paper describes the discovery of the nuclear protein San1. Together with reference 101, this study defines a new mechanism whereby this E3 ligase recognizes hydrophobic stretches of amino acids in unfolded protein targets. This represents a new paradigm in protein quality control
101. Rosenbaum JC, et al. Disorder targets disorder in nuclear quality control degradation: a disordered ubiquitin ligase directly recognizes its misfolded substrates. *Mol. Cell.* 2011; 41:93–106. [PubMed: 21211726]

102. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and  $\beta$ -TrCP: tipping the scales of cancer. *Nature Rev. Cancer*. 2008; 8:438–449. [PubMed: 18500245]
103. Singh BN, et al. Nonhistone protein acetylation as cancer therapy targets. *Expert Rev. Anticancer Ther*. 2010; 10:935–954. [PubMed: 20553216]
104. Suganuma T, et al. ATAC is a double histone acetyltransferase complex that stimulates nucleosome sliding. *Nature Struct. Mol. Biol*. 2008; 15:364–372. [PubMed: 18327268]
105. Suganuma T, et al. The ATAC acetyltransferase complex coordinates MAP kinases to regulate JNK target genes. *Cell*. 2010; 142:726–736. [PubMed: 20813260] This study provides compelling evidence for a signalling scaffold that synchronizes protein acetylation and phosphorylation events
106. Jiang W, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. *Mol. Cell*. 2011; 43:33–44. [PubMed: 21726808]
107. Choudhary C, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science*. 2009; 325:834–840. [PubMed: 19608861]
108. Wang Q, et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. *Science*. 2010; 327:1004–1007. [PubMed: 20167787]
109. Zhao S, et al. Regulation of cellular metabolism by protein lysine acetylation. *Science*. 2010; 327:1000–1004. [PubMed: 20167786]
110. Kranz JE, Satterberg B, Elion EA. The MAP kinase Fus3 associates with and phosphorylates the upstream signaling component Ste5. *Genes Dev*. 1994; 8:313–327. [PubMed: 8314085]
111. Sette C, Inouye CJ, Stroschein SL, Iaquina PJ, Thorner J. Mutational analysis suggests that activation of the yeast pheromone response mitogen-activated protein kinase pathway involves conformational changes in the Ste5 scaffold protein. *Mol. Biol. Cell*. 2000; 11:4033–4049. [PubMed: 11071925]
112. Elion EA. The Ste5p scaffold. *J. Cell Sci*. 2001; 114:3967–3978. [PubMed: 11739629]
113. Strickfaden SC, et al. A mechanism for cell-cycle regulation of MAP kinase signaling in a yeast differentiation pathway. *Cell*. 2007; 128:519–531. [PubMed: 17289571] This is an elegant study that describes the role of MAPKs in the modulation of yeast cell division
114. Malleshaiah MK, Shahrezaei V, Swain PS, Michnick SW. The scaffold protein Ste5 directly controls a switch-like mating decision in yeast. *Nature*. 2010; 465:101–105. [PubMed: 20400943]
115. Zalatan JG, Coyle SM, Rajan S, Sidhu SS, Lim WA. Conformational control of the Ste5 scaffold protein insulates against MAP kinase misactivation. *Science*. 2012; 337:1218–1222. [PubMed: 22878499]
116. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. A mammalian scaffold complex that selectively mediates MAP kinase activation. *Science*. 1998; 281:1671–1674. [PubMed: 9733513]
117. Bonny C, Nicod P, Waeber G. IB1, a JIP-1-related nuclear protein present in insulin-secreting cells. *J. Biol. Chem*. 1998; 273:1843–1846. [PubMed: 9442013]
118. Fu MM, Holzbaur EL. JIP1 regulates the directionality of APP axonal transport by coordinating kinesin and dynein motors. *J. Cell Biol*. 2013; 202:495–508. [PubMed: 23897889]
119. Willoughby EA, Perkins GR, Collins MK, Whitmarsh AJ. The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK. *J. Biol. Chem*. 2003; 278:10731–10736. [PubMed: 12524447]
120. Fu MM, Nirschl JJ, Holzbaur EL. LC3 binding to the scaffolding protein JIP1 regulates processive dynein-driven transport of autophagosomes. *Dev. Cell*. 2014; 29:577–590. [PubMed: 24914561] This study provides mechanistic evidence for the JIP1 scaffold as a dynamic regulator of organelle movement
121. Robinson CV, Sali A, Baumeister W. The molecular sociology of the cell. *Nature*. 2007; 450:973–982. [PubMed: 18075576]
122. Heck AJ. Native mass spectrometry: a bridge between interactomics and structural biology. *Nature Methods*. 2008; 5:927–933. [PubMed: 18974734]
123. Gold MG, et al. Architecture and dynamics of an A-kinase anchoring protein 79 (AKAP79) signaling complex. *Proc. Natl Acad. Sci. USA*. 2011; 108:6426–6431. [PubMed: 21464287]

124. Jain A, et al. Probing cellular protein complexes using single-molecule pull-down. *Nature*. 2011; 473:484–488. [PubMed: 21614075]
125. Means CK, et al. An entirely specific type I A-kinase anchoring protein that can sequester two molecules of protein kinase A at mitochondria. *Proc. Natl Acad. Sci. USA*. 2011; 108:E1227–E1235. [PubMed: 22084075]
126. Cao E, Liao M, Cheng Y, Julius D. TRPV1 structures in distinct conformations reveal activation mechanisms. *Nature*. 2013; 504:113–118. [PubMed: 24305161]
127. Li X, et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. *Nature Methods*. 2013; 10:584–590. [PubMed: 23644547]
128. Bai XC, Fernandez IS, McMullan G, Scheres SH. Ribosome structures to near-atomic resolution from thirty thousand cryo-EM particles. *eLife*. 2013; 2:e00461. [PubMed: 23427024]
129. Lu P, et al. Three-dimensional structure of human  $\gamma$ -secretase. *Nature*. 2014; 512:166–170. [PubMed: 25043039]
130. Scheres SH. Beam-induced motion correction for sub-megadalton cryo-EM particles. *eLife*. 2014; 3:e03665. [PubMed: 25122622]
131. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. *Genes Cancer*. 2011; 2:344–358. [PubMed: 21779504]
132. Hatzivassiliou G, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature*. 2010; 464:431–435. [PubMed: 20130576]
133. Halaban R, et al. PLX4032, a selective BRAF<sup>V600E</sup> kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF<sup>WT</sup> melanoma cells. *Pigment Cell Melanoma Res*. 2010; 23:190–200. [PubMed: 20149136]
134. Rubinstein JC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. *J. Transl. Med*. 2010; 8:67. [PubMed: 20630094]
135. Reiterer V, Eyers PA, Farhan H. Day of the dead: pseudokinases and pseudophosphatases in physiology and disease. *Trends Cell Biol*. 2014; 24:489–505. [PubMed: 24818526]
136. Shi F, Lemmon MA. KSR plays CRAF-ty. *Science*. 2011; 332:1043–1044. [PubMed: 21617065]
137. Carnegie GK, Means CK, Scott JD. A-kinase anchoring proteins: from protein complexes to physiology and disease. *IUBMB Life*. 2009; 61:394–406. [PubMed: 19319965]
138. Li H, et al. Balanced interactions of calcineurin with AKAP79 regulate Ca<sup>2+</sup>-calcineurin-NFAT signaling. *Nature Struct. Mol. Biol*. 2012; 19:337–345. [PubMed: 22343722]
139. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. *Annu. Rev. Cell Dev. Biol*. 2003; 19:91–118. [PubMed: 14570565]
140. Scholten A, et al. Analysis of the cGMP/cAMP interactome using a chemical proteomics approach in mammalian heart tissue validates sphingosine kinase type 1-interacting protein as a genuine and highly abundant AKAP. *J. Proteome Res*. 2006; 5:1435–1447. [PubMed: 16739995]

**Box 1****Pseudokinases and pseudophosphatases****Pseudokinases**


Pseudokinases contain amino acid substitutions within the conserved kinase catalytic core that impair phosphoryl transfer<sup>23</sup>. As indicated in part **a** of the figure (structural data from the RCSB Protein Data Bank (PDB) code: 3C9W), many of these substitutions reside within one of three invariant motifs: the VAIK motif, which engages ATP and positions it for phosphoryl transfer; the DFG motif, which binds to  $Mg^{2+}$  to coordinate ATP binding; and the HRD catalytic motif, which participates in proton transfer<sup>22</sup>. Recent structural studies indicate that some pseudokinases retain the ability to tightly bind nucleotides for delivery to a binding partner with kinase activity<sup>30</sup>. Thus, nucleotide release from these pseudokinases has a direct effect on the catalytic efficiency of the active kinase binding partners. These findings have contributed to the recent notion that serine/threonine-like pseudokinases can allosterically regulate their associated active kinases. Consequently, some pseudokinases are now considered to be viable drug targets.

Interest in the signalling pathway that is scaffolded by kinase suppressor of RAS (KSR), a pseudokinase, has been stimulated by clinical evidence that activating mutations in *RAS* are found in ~30% of all human tumours<sup>131</sup>. Understandably, the *RAS*–*RAF*–*MEK*–*ERK* signalling cascade is a prime target for therapeutic intervention. However, the outcome of several drug-discovery ventures has been quite surprising. Although certain ATP analogue drugs that inhibit *BRAF* — such as sorafenib (Nexavar; Bayer and Onyx Pharmaceuticals) and dabrafenib (Tafinlar; GlaxoSmithKline) — effectively combat renal and hepatic carcinomas and melanomas, other *BRAF* inhibitors, such as vemurafenib (Zelboraf; Plexxikon and Genetech), paradoxically stimulate tumour growth in cells with normal (non-mutant) *BRAF*. Accordingly, vemurafenib can only be prescribed to patients with melanoma who have *BRAF*-V600E or *BRAF*-V600K substitutions, which affect the active site of this kinase<sup>132–134</sup>. Some of these anomalies may be explained by the complex interplay between *RAF*s, other members of the *ERK* cascade and its activator, *KSR*.

**Pseudophosphatases**


The concept of pseudophosphatases was first proposed to account for the unexpected functional roles of additional phosphotyrosine phosphatase homology domains that were identified in CD45, RPTP $\gamma$  and RPTP $\zeta$ <sup>44</sup>. These structured regions seemed to have little

or no phosphatase activity against *in vitro* substrates<sup>43,44</sup>. A combination of biochemistry and bioinformatics has suggested that ~8% of the human phosphatome (17 out of 215 members) encodes pseudophosphatases<sup>135</sup>. A putative role for this burgeoning family of pseudoenzymes is to regulate signalling by functioning as conformational clamps that bind to phosphosubstrates and prevent their dephosphorylation (see the figure, part **b**; structural data from PDB code: 3N5U), thus indirectly augmenting kinase activity in various cellular contexts. The discovery of small molecules that can either function as inhibitors of activation or directly target these protein-protein interfaces is taking hold as a future health objective.




### Figure 1. Properties of adaptor, docking and scaffold proteins

The figure depicts the distinguishing features of signal-organizing proteins and of scaffold proteins. Adaptor proteins, such as growth factor receptor-bound protein 2 (GRB2) (part **a**), and membrane-associated docking proteins, such as insulin receptor substrate 1 (IRS1) (part **b**), are both composed of protein-interaction modules that recruit signalling enzymes near transmembrane receptors<sup>21</sup>. Essential features of scaffold proteins (shown in green) include the ability to hold in place successive members of a signalling cascade (part **c**), focus enzyme activity at a particular site of action (part **d**) and provide a molecular platform for the coordinated regulation of a particular effector protein by signal transduction and signal termination enzymes (part **e**). Phosphate groups are depicted as orange circles. PDK1, phosphoinositide-dependent kinase 1; PH, pleckstrin homology domain; PTB, phosphotyrosine-binding domain; SH2, SRC homology 2; SOS, son of sevenless.



### Figure 2. Scaffold functions of pseudokinases and pseudophosphatases

Three prototypical examples of pseudokinase and pseudophosphatase function are shown. These non-catalytic proteins (shown in green) function as enzyme scaffolds and also allosterically modulate the activity of signalling enzymes. **a** | The tumour suppressor protein liver kinase B1 (LKB1) and the pseudokinase scaffold protein STRAD form a complex with MO25 (REF. 22). This heterotrimeric complex induces the ATP-bound STRAD to adopt a closed conformation that is reminiscent of an active protein kinase and that is able to activate LKB1. Interaction with MO25 stabilizes the active conformation of LKB1 (REF. 33). **b** | Kinase suppressor of RAS (KSR) is a multifunctional binding protein that brings together the three members of the conventional RAF–MEK–ERK–MAPK cascade<sup>36,136</sup>. **c** | The pseudophosphatase serine/threonine/tyrosine-interacting protein (STYX) competes with the active dual-specificity phosphatase 4 (DUSP4) for binding to ERK1 and ERK2 in the nucleus<sup>135</sup>. Through this mechanism, STYX traps active elements of the ERK cascade in the nucleus<sup>47</sup>. Phosphate groups are depicted as orange circles.



**Figure 3. Local coordination of second-messenger signalling by A-kinase anchor proteins**

A-kinase anchor proteins (AKAPs) constrain protein kinase A (PKA) and other second-messenger-regulated signalling enzymes to form macromolecular units<sup>137</sup>. **a** | A composite negative-stain electron microscopy image (class average) of the intact type II PKA–AKAP18 $\gamma$  complex is shown. **b** | Three-dimensional reconstructions reveal that the complex has a heteropentameric protein assembly (containing one AKAP18 subunit, two regulatory type II (RII) subunits of PKA and two catalytic (C) subunits of PKA<sup>55</sup>). The flexible tripartite configuration enables the associated catalytic subunits to have a radius of motion of up to 300 Å. **c** | Mouse AKAP150 is a multifunctional anchor protein that coordinates different combinations of second-messenger-regulated enzymes. The figure shows an assembly of PKA and serine/threonine protein phosphatase 2B (PP2B) maintained by AKAP150. A structural model of the interface between AKAP150 and a pair of PP2B holoenzymes shows that protein–protein interactions occur through a modified PIXIT phosphatase-interaction motif<sup>123,138</sup>. **d** | An established role for AKAP150 is the modulation of the phosphorylation events that control glutamate receptor ion channels. AKAP150-associated PKA and PP2B provide bidirectional regulation of glutamate receptor 1 (GluR1) phosphorylation at Ser845. Anchored PKA-mediated phosphorylation of GluR1 at Ser845 augments the membrane insertion of GluR1 at dendrites<sup>70</sup>. PP2B-mediated dephosphorylation of GluR1 at this site reverses this process<sup>70</sup>. **e** | In other cellular contexts, AKAP150 coordinates metabolic signalling events. AKAP150-associated PP2B activity modulates aspects of the insulin-responsive PI3K–phosphoinositide-dependent kinase 1 (PDK1)–AKT signalling cascade in skeletal muscle to control insulin sensitivity<sup>79</sup>. Scaffold




proteins are depicted in green; phosphate groups are depicted as orange circles. IRS1, insulin receptor substrate 1. Parts **a** and **b** are adapted from REF. 55, eLife Sciences Publications. Part **c** is adapted with permission from REF. 79, John Wiley & Sons.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



#### Figure 4. Signal termination scaffolds

Scaffold proteins that target phosphatases and the enzymes that control protein ubiquitylation, acetylation and deacetylation are shown. **a** | A ribbon diagram of serine/threonine protein phosphatase 1 (PP1) catalytic subunit (turquoise) in a complex with a KVXF-motif peptide derived from the glycogen-targeting subunit  $G_M$  (green)<sup>25</sup> is shown. Important regions for peptide binding are shown in red. The peptide-binding channel of PP1 lies at the interface of the two  $\beta$ -sheets of a  $\beta$ -sandwich. **b** | An example of a higher-order PP1 scaffold is depicted. A phosphatase–kinase scaffold tightly modulates smooth muscle contraction<sup>87</sup>. The proximity of the activator protein kinase G (PKG) and the inhibitory RHO-associated protein kinase 1 (ROCK1) provides bidirectional control of PP1 when tethered to its scaffold protein, the myosin-targeting PP1 subunit MYPT1, and the myosin light chains (MLCs). **c** | A second example of a higher-order PP1 scaffold is shown. When in a complex with MRAS, the phosphatase-targeting subunit SHOC2 competes with another scaffold protein, SCRIB, for interaction with PP1. Thus, ERK signalling is antagonized by the SHOC2-mediated dephosphorylation of RAF and is facilitated when the phosphatase is sequestered by SCRIB<sup>95</sup>. Ubiquitylation and acetylation are important molecular switches controlled by the protein–protein interactions within scaffolds. **d** | By recognizing the exposed hydrophobicity of misfolded proteins, the yeast E3 ligase San1 functions as a scaffold and is able to target misfolded proteins for ubiquitylation and proteasomal degradation<sup>101</sup>. **e** | The scaffold formed by the phosphoenolpyruvate carboxykinase 1 (PEPCK1) efficiently responds to changes in glucose levels through its associated metabolic enzymes<sup>109</sup>. In the presence of high levels of glucose, the associated acetyltransferase p300 acetylates PEPCK1, targeting it for ubiquitylation and subsequent degradation by the E3


ubiquitin protein ligase UBR5 that is recruited to the complex. When the glucose level is low, the deacetylase sirtuin 2 (SIRT2) blocks this process. Acetyl groups are depicted as red circles, phosphate groups are depicted as orange circles, and ubiquitin groups are depicted as blue circles. NO, nitric oxide. Part **a** is adapted with permission from REF. 25, John Wiley & Sons.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



**Figure 5. Scaffold proteins that function as molecular switches**

MAPK scaffold proteins in yeast and mammals are depicted. **a** | The yeast scaffold protein Ste5 assembles a MAPK cascade that includes Ste11, Ste7 and Fus3 at the cell membrane. However, phosphorylation of Ste5 by cyclin-dependent kinase (Cdk) inhibits this process<sup>112,115</sup>. **b** | The JUN amino-terminal kinase (JNK) and p38 MAPK scaffold proteins of the JNK-interacting protein (JIP) family associate with motor proteins to transport various cargo proteins along microtubules<sup>139</sup>. Phosphorylation of Ser421 on JIP1 links the mixed lineage kinase 3 (MLK3)–MEK7–JNK cascade to the motor protein kinesin for forward motion along the microtubule, whereas dephosphorylation of this residue functions as a switch for retrograde movement facilitated by interaction with dynactin (not shown)<sup>118</sup>. Phosphate groups are depicted as orange circles. GPCR, G protein-coupled receptor.



**Figure 6. Emergent technologies for the analysis of signalling scaffolds**

Three emergent biophysical approaches have the potential to enhance the molecular dissection of macromolecular signalling scaffolds. Native mass spectrometry enables the investigation of intact protein complexes<sup>121,140</sup>. This top-down mass spectrometry approach probes the quaternary structure of protein complexes suspended in volatile buffers, thus enabling accurate calculation of their mass<sup>123</sup>. An A-kinase anchoring protein 79 (AKAP79)–kinase–phosphatase sub-complex was first assessed by SDS–PAGE (part **a**). Next, the molecular mass of the sub-complex was derived by native mass spectrometry (part

**b**). The quantitative information that was obtained was used to determine a more refined model of the quaternary structure of this macromolecular complex (part **c**). Single-molecule pull-down photobleaching (SiMPull) is a sensitive new assay that combines a modified pull-down assay (part **d**) with single-molecule photobleaching of fluorescently tagged proteins (part **e**) to enable direct analysis of individual protein complexes<sup>124</sup>. SiMPull can be used to derive the ratio of distinct protein complexes assembled on a specific population of scaffold protein. Electron microscopes have sufficient resolving power for structural studies of macromolecules. Recent technical innovations, including a new generation of direct-detection camera and the development of more sophisticated data-processing packages, have markedly increased the resolution of cryo-electron microscopy for higher-order macromolecular complexes<sup>127,128</sup>. Smaller complexes (molecular weight (MW) <300,000 kDa) can be resolved by negative-stain electron microscopy (part **f**). Class averages of negative-stain electron microscopy particles show three perspectives of the AKAP18 $\gamma$ -protein kinase A (PKA) complex<sup>55</sup>. The density map of the AKAP18 $\gamma$ -PKA holoenzyme complex can be overlaid with structural models from the RCSB Protein Data Bank (PDB) coordinates for AKAP18 $\gamma$  (PDB code: 3J4Q), and the type II $\alpha$  regulatory (RII $\alpha$ ) and catalytic (C) subunits of PKA to enable pseudo-atomic modelling (part **g**). CaM, calmodulin; FLAG, DYKDDDDK polypeptide tag; m/z, mass-to-charge ratio; PEG, polyethylene glycol; PP2B, protein phosphatase 2B; TIRF, total internal reflection fluorescence; YFP, yellow fluorescent protein. Parts **a** and **b** are adapted from REF. 123, US National Academy of Sciences; part **e** is adapted from REF. 125, US National Academy of Sciences; and part **g** is adapted from REF. 55, eLife Sciences Publications.